



# SZABO SCANDIC

Part of Europa Biosite

## Produktinformation



Forschungsprodukte & Biochemikalien



Zellkultur & Verbrauchsmaterial



Diagnostik & molekulare Diagnostik



Laborgeräte & Service

Weitere Information auf den folgenden Seiten!  
See the following pages for more information!



### Lieferung & Zahlungsart

siehe unsere [Liefer- und Versandbedingungen](#)

### Zuschläge

- Mindermengenzuschlag
- Trockeneiszuschlag
- Gefahrgutzuschlag
- Expressversand

### SZABO-SCANDIC Handels GmbH

Quellenstraße 110, A-1100 Wien

T. +43(0)1 489 3961-0

F. +43(0)1 489 3961-7


[mail@szabo-scandic.com](mailto:mail@szabo-scandic.com)

[www.szabo-scandic.com](http://www.szabo-scandic.com)

[linkedin.com/company/szaboscandic](https://www.linkedin.com/company/szaboscandic) 

## LDN-57444

Cat. No.:	HY-18637
CAS No.:	668467-91-2
Molecular Formula:	C <sub>17</sub> H <sub>11</sub> Cl <sub>3</sub> N <sub>2</sub> O <sub>3</sub>
Molecular Weight:	397.64
Target:	Deubiquitinase; Apoptosis
Pathway:	Cell Cycle/DNA Damage; Apoptosis
Storage:	<div> Powder -20°C 3 years </div> <div> 4°C 2 years </div> <div> In solvent -80°C 6 months </div> <div> -20°C 1 month </div>



### SOLVENT & SOLUBILITY

In Vitro	DMSO : 25 mg/mL (62.87 mM; Need ultrasonic)				
	Preparing Stock Solutions	<div>Solvent Concentration</div> <div>Mass</div>	1 mg	5 mg	10 mg
		1 mM	2.5148 mL	12.5742 mL	25.1484 mL
		5 mM	0.5030 mL	2.5148 mL	5.0297 mL
		10 mM	0.2515 mL	1.2574 mL	2.5148 mL
Please refer to the solubility information to select the appropriate solvent.					
In Vivo	1. Add each solvent one by one: 50% PEG300 >> 50% saline Solubility: 10 mg/mL (25.15 mM); Suspended solution; Need ultrasonic				
	2. Add each solvent one by one: 10% DMSO >> 90% corn oil Solubility: ≥ 2.5 mg/mL (6.29 mM); Clear solution				

### BIOLOGICAL ACTIVITY

Description	LDN-57444 is a reversible, competitive and site-directed inhibitor of ubiquitin C-terminal hydrolase L1 (UCH-L1), with an IC <sub>50</sub> of 0.88 μM and a K <sub>i</sub> of 0.40 μM; LDN-57444 also suppresses UCH-L3 activity, with an IC <sub>50</sub> of 25 μM.
IC <sub>50</sub> & Target	IC <sub>50</sub> : 0.88 μM (UCH-L1), 25 μM (UCH-L3) <sup>[1]</sup> K <sub>i</sub> : 0.40 μM (UCH-L1) <sup>[1]</sup>
In Vitro	LDN-57444 is a reversible, competitive inhibitor of UCH-L1, with an IC <sub>50</sub> of 0.88 μM, and also suppresses UCH-L3 activity, with an IC <sub>50</sub> of 25 μM <sup>[1]</sup> . LDN-57444 (LDN, 5 μM for 1 hr) inhibits 70% of Uch activity in hippocampal slices of the mouse brain. LDN-57444 (5 μM for 2 hr) does not reduce potentiation further in APP/PS1 slices or in wt slices exposed to 200 nM Aβ <sup>[2]</sup> . LDN-57444 (25-100 μM) inhibits ubiquitin-proteasome activity dose-dependently in SK-N-SH cells. LDN-57444 (50 μM) also

	<p>induces apoptotic cell death, causes the endoplasmic reticulum stress and results in expression of spliced XBP-1(XBP-1s, 48KD) in SK-N-SH cells<sup>[3]</sup>.</p> <p>MCE has not independently confirmed the accuracy of these methods. They are for reference only.</p>
<b>In Vivo</b>	<p>LDN-57444 (0.4 mg/kg, i.p.) blocks the beneficial effect of V-Uch-L1, and worsens contextual conditioning performance as the mice are exposed to the context at 1, 7, 14, and 21 days after training<sup>[2]</sup>.</p> <p>MCE has not independently confirmed the accuracy of these methods. They are for reference only.</p>

## PROTOCOL

<b>Kinase Assay</b> <sup>[1]</sup>	<p>To start an assay, 0.5 µL of 5 mg/mL test compound (including LDN-57444, about 50 µM final reaction concentration) or DMSO control is aliquoted into each well. Both enzyme and substrate are prepared in UCH reaction buffer (50 mM Tris-HCl [pH 7.6], 0.5 mM EDTA, 5 mM DTT, and 0.5 mg/mL ovalbumin). 25 µL of 0.6 nM UCH-L1 is then added to each well except substrate control wells, followed by plate shaking for 45-60 s on an automatic shaker. The enzyme/compound mixture is incubated at room temperature for 30 min before 25 µL of 200 nM Ub-AMC is added to initiate the enzyme reaction. The reaction mixture (300 pM UCH-L1, 100 nM Ubiquitin-AMC with 2.5 µg test compound) is incubated at room temperature for 30 additional minutes prior to quenching the reaction by the addition of 10 µL 500 mM acetic acid per well. The fluorescence emission intensity is measured on a LJL Analyst using a coumarin filter set (ex = 365 nm, em = 450 nm) and is subtracted by the intrinsic compound fluorescence to reveal the enzyme activity. A DMSO control (0.5 µL of DMSO, 25 µL of UCH-L1, 25 µL of ubiquitin-AMC, 10 µL of acetic acid), enzyme control (25 µL of UCH-L1, 25 µL of buffer, 10 µL of acetic acid), substrate control (25 µL of buffer, 25 µL of ubiquitin-AMC, 10 µL of acetic acid), and inhibitor control (0.5 µL of ubiquitin aldehyde [100 nM stock], 25 µL of UCH-L1, 25 µL of ubiquitin-AMC, 10 µL of acetic acid) are also performed in each assay plate to ensure quality and reproducibility. The UCH-L1 enzymatic reactions are manually repeated twice using the same protocol to confirm the results for the hit compounds from the primary robot-assisted screen<sup>[1]</sup>.</p> <p>MCE has not independently confirmed the accuracy of these methods. They are for reference only.</p>
<b>Cell Assay</b> <sup>[3]</sup>	<p>Cell viability is measured by a quantitative colorimetric assay with MTT. After drug treatment SK-N-SH cells are incubated for 4 h with 5 g/L MTT and then DMSO is added for 15 min. The absorption is quantified at 570 nm using a micro-plate reader <sup>[3]</sup>.</p> <p>MCE has not independently confirmed the accuracy of these methods. They are for reference only.</p>
<b>Animal Administration</b> <sup>[2]</sup>	<p>Each animal is placed individually into the conditioning chamber. The electric current is gradually increased (0.1 mA for 1 sec. at 30 sec. intervals increasing the shock intensity by 0.1 mA to 0.7 mA). Animal behavior is evaluated for the first visible response to the shock (flinch), the first extreme motor response (run/jump), and the first vocalized distress (scream). Threshold to flinching, jumping, and screaming is quantified for each animal by averaging of the shock intensity at which each animal manifests a behavioral response of that type to the foot shock. Visual, motor, and motivation skills are also tested with visible platform training by measuring the time and the speed to reach a visible platform placed within a pool filled with water. Both time to reach the platform and swimming speed are recorded and analyzed with a video tracking system. No difference is observed among different groups of mice in the experiments in which fear conditioning is tested both in the presence of LDN-57444 (LDN) and TAT fusion proteins. To decide the time of administration of LDN-57444, a series of preliminary experiments are performed in which the inhibitor is injected intra-peritoneally at different intervals (4 hrs before, 1 hr before, 1 hr after and 4 hrs after) from the electric shock. During the training phase, there is no difference in the freezing of LDN-57444- or vehicle-injected mice<sup>[2]</sup>.</p> <p>MCE has not independently confirmed the accuracy of these methods. They are for reference only.</p>

## CUSTOMER VALIDATION

- Nat Commun. 2022 Mar 31;13(1):1700.
- EMBO J. 2022 Jul 11;e108791.

- Cell Chem Biol. 2021 Apr 27;S2451-9456(21)00213-0.
- J Med Chem. 2022 Oct 11.
- Cancer Sci. 2020 Sep;111(9):3174-3183.

See more customer validations on [www.MedChemExpress.com](http://www.MedChemExpress.com)

## REFERENCES

---

- [1]. Liu Y, et al. Discovery of inhibitors that elucidate the role of UCH-L1 activity in the H1299 lung cancer cell line. Chem Biol. 2003 Sep;10(9):837-46.
- [2]. Gong B, et al. Ubiquitin hydrolase Uch-L1 rescues beta-amyloid-induced decreases in synaptic function and contextual memory. Cell. 2006 Aug 25;126(4):775-88.
- [3]. Tan YY, et al. Endoplasmic reticulum stress contributes to the cell death induced by UCH-L1 inhibitor. Mol Cell Biochem. 2008 Nov;318(1-2):109-15.
- 

**Caution: Product has not been fully validated for medical applications. For research use only.**

Tel: 609-228-6898

Fax: 609-228-5909

E-mail: [tech@MedChemExpress.com](mailto:tech@MedChemExpress.com)

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA